Sutro Biopharma Stock Today
| STRO Stock | USD 2.51 0.02 0.79% |
Performance0 of 100
| Odds Of DistressOver 51
|
Sutro Biopharma is selling at 2.51 as of the 25th of November 2024; that is 0.79% down since the beginning of the trading day. The stock's open price was 2.53. Sutro Biopharma has 51 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Sutro Biopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of September 2018 | Category Healthcare | Classification Health Care |
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. Sutro Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 82.46 M outstanding shares of which 2.4 M shares are at this time shorted by private and institutional investors with about 5.47 trading days to cover. More on Sutro Biopharma
Moving together with Sutro Stock
Moving against Sutro Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Sutro Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, OBX Technology GR, Oslo All Share, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSutro Biopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sutro Biopharma's financial leverage. It provides some insight into what part of Sutro Biopharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sutro Biopharma (STRO) is traded on NASDAQ Exchange in USA. It is located in 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 302 people. Sutro Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 206.97 M. Sutro Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 82.46 M outstanding shares of which 2.4 M shares are at this time shorted by private and institutional investors with about 5.47 trading days to cover.
Sutro Biopharma currently holds about 225.64 M in cash with (111.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Sutro Biopharma Probability Of Bankruptcy
Ownership AllocationSutro Biopharma shows a total of 82.46 Million outstanding shares. The majority of Sutro Biopharma outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Sutro Biopharma to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Sutro Biopharma. Please pay attention to any change in the institutional holdings of Sutro Biopharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Sutro Ownership Details
Sutro Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Eversept Partners, Llc | 2024-09-30 | 1.8 M | |
| Parkman Healthcare Partners Llc | 2024-06-30 | 1.8 M | |
| State Street Corp | 2024-06-30 | 1.6 M | |
| Baillie Gifford & Co Limited. | 2024-09-30 | 1.5 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 1 M | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 980.3 K | |
| Nuveen Asset Management, Llc | 2024-06-30 | 905.4 K | |
| Renaissance Technologies Corp | 2024-09-30 | 828.1 K | |
| Jacobs Levy Equity Management, Inc. | 2024-09-30 | 821.7 K | |
| Suvretta Capital Management, Llc | 2024-06-30 | 7.7 M | |
| Blackrock Inc | 2024-06-30 | 6.9 M |
Sutro Biopharma Historical Income Statement
Sutro Stock Against Markets
Sutro Biopharma Corporate Management
| Barbara Leyman | Chief Officer | Profile | |
| Shabbir Anik | Chief Technical Operations Officer | Profile | |
| William JD | CEO Director | Profile | |
| Nicki Vasquez | Chief Officer | Profile | |
| Annie MBA | VP Relations | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Revenue Per Share 2.253 | Quarterly Revenue Growth (0.50) | Return On Assets (0.18) | Return On Equity (1.11) |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.